US6117641A
(en)
|
1996-04-11 |
2000-09-12 |
Mitotix, Inc. |
Assays and reagents for identifying anti-fungal agents and uses related thereto
|
KR20000005397A
(ko)
|
1996-04-11 |
2000-01-25 |
맨수리 무잠밀 엠 |
항-진균제를확인하기위한검정방법및시약,및이의용도
|
US6727082B1
(en)
|
1996-04-11 |
2004-04-27 |
Gpc Biotech Inc. |
Assays and reagents for identifying anti-fungal agents, and uses related thereto
|
CA2260216A1
(en)
|
1996-07-15 |
1998-01-22 |
Bristol-Myers Squibb Company |
Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase
|
JP2001514191A
(ja)
*
|
1997-08-27 |
2001-09-11 |
メルク エンド カムパニー インコーポレーテッド |
癌の治療方法
|
AU735366B2
(en)
*
|
1997-09-29 |
2001-07-05 |
Bristol-Myers Squibb Company |
Inhibitors of farnesyl protein transferase
|
US6458783B1
(en)
*
|
1997-09-29 |
2002-10-01 |
Bristol-Myers Squibb Company |
Non-imidazole benzodiazepine inhibitors of farnesyl protein transferase
|
KR100704977B1
(ko)
*
|
1997-12-22 |
2007-04-09 |
바이엘 코포레이션 |
대칭성 및 비대칭성 치환디페닐우레아를 이용한 raf키나제의 저해
|
US6071903A
(en)
*
|
1998-01-27 |
2000-06-06 |
American Cyanamid Company |
2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepine-3-hydroxyamic acids
|
US6423519B1
(en)
*
|
1998-07-15 |
2002-07-23 |
Gpc Biotech Inc. |
Compositions and methods for inhibiting fungal growth
|
US6316436B1
(en)
|
1998-12-08 |
2001-11-13 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
AU2477400A
(en)
|
1998-12-08 |
2000-06-26 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
EP2298311B1
(de)
|
1999-01-13 |
2012-05-09 |
Bayer HealthCare LLC |
Omega-carboxyarylsubstituierte-Diphenyl-Harnstoffe als p38-Kinasehemmer
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
RU2230062C2
(ru)
*
|
1999-01-21 |
2004-06-10 |
Бристол-Маерс Сквибб Ко. |
Комплекс ингибитора ras-фарнезилтрансферазы, композиция ингибитора ras-фарнезилтрансферазы, фармацевтическая композиция
|
CA2363169A1
(en)
*
|
1999-03-03 |
2000-09-08 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
US7125875B2
(en)
|
1999-04-15 |
2006-10-24 |
Bristol-Myers Squibb Company |
Cyclic protein tyrosine kinase inhibitors
|
AU779089B2
(en)
|
1999-04-15 |
2005-01-06 |
Bristol-Myers Squibb Holdings Ireland Unlimited Company |
Cyclic protein tyrosine kinase inhibitors
|
US20060025388A1
(en)
|
1999-04-30 |
2006-02-02 |
Glick Gary D |
Compositions and methods relating to novel compounds and targets thereof
|
EP1187605A4
(de)
*
|
1999-06-18 |
2004-05-26 |
Thyreos Corp |
BEHANDLUNG DER NICHT BöSARTIGEN KRANKHEITEN MIT RAS-ANTAGONISTEN
|
US20020115696A1
(en)
|
1999-06-18 |
2002-08-22 |
Yoel Kloog |
Treatment of post-angioplasty restenosis and atherosclerosis with ras antagonists
|
MXPA02000242A
(es)
|
1999-06-30 |
2004-09-10 |
Prescient Neuropharma Inc |
Analogos de 2-aminoindano.
|
FR2796943A1
(fr)
*
|
1999-07-30 |
2001-02-02 |
Aventis Pharma Sa |
Derives de benzoxazinnes, leur procede de preparation et leur utilisation en therapeutique
|
EP1088821A1
(de)
|
1999-09-28 |
2001-04-04 |
Applied Research Systems ARS Holding N.V. |
Pharmazeutisch wirksamer Sulfonamid Derivate
|
US6100395A
(en)
*
|
2000-01-10 |
2000-08-08 |
Bristol-Myers Squibb Company |
Reductive alkylation of secondary amines with hydrosilane
|
EP1267848B1
(de)
|
2000-02-24 |
2007-10-17 |
Janssen Pharmaceutica N.V. |
Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
|
TWI310684B
(en)
*
|
2000-03-27 |
2009-06-11 |
Bristol Myers Squibb Co |
Synergistic pharmaceutical kits for treating cancer
|
WO2001076629A1
(fr)
*
|
2000-04-07 |
2001-10-18 |
Takeda Chemical Industries, Ltd. |
Promoteurs solubles de secretion du precurseur de la proteine beta-amyoide
|
DE60139080D1
(de)
*
|
2000-11-21 |
2009-08-06 |
Janssen Pharmaceutica Nv |
Farnesyltransferase hemmende benzoheterocyclische derivate
|
ES2261523T3
(es)
*
|
2000-11-28 |
2006-11-16 |
Janssen Pharmaceutica N.V. |
Inhibidores de farnesil proteina transferasa para el tratamiento de enfermedad intestinal inflamatoria.
|
US20040067968A1
(en)
*
|
2000-12-27 |
2004-04-08 |
Angibaud Patrick Rene |
Farnesyl transferase inhibiting 4-heterocyclyl quinoline and quinazoline
|
US7129356B2
(en)
*
|
2000-12-27 |
2006-10-31 |
Janssen Pharmaceutica N.V. |
Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives
|
AU2002236813A1
(en)
*
|
2001-01-22 |
2002-07-30 |
Schering Corporation |
Treatment of malaria with farnesyl protein transferase inhibitors
|
BRPI0206509B8
(pt)
|
2001-01-25 |
2021-05-25 |
R Pharm Us Operating Llc |
processo para formular, para administração parenteral, um análogo de epotilona, preparação farmacêutica, processo para formar uma composição farmacêutica para administração parental, composição farmacêutica e uso de um análogo de epotilona na preparação de uma composição farmacêutica para o tratamento de câncer
|
US7759323B2
(en)
|
2001-05-22 |
2010-07-20 |
Eisai R & D Management Co., Ltd. |
Highly purified antiendotoxin compound
|
US6905813B2
(en)
*
|
2001-08-29 |
2005-06-14 |
Chugai Photo Chemical Co., Ltd. |
Processing agent for silver halide color photosensitive material and processing method thereof
|
US20030134846A1
(en)
*
|
2001-10-09 |
2003-07-17 |
Schering Corporation |
Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors
|
AU2002359412A1
(en)
*
|
2001-11-13 |
2003-05-26 |
Bristol-Myers Squibb Company |
Process for the preparation of 3,7-disubstituted-2,3,4,5- tetrahydro-1h-1,4-benzodiazepine compounds
|
WO2003068228A1
(en)
|
2002-02-11 |
2003-08-21 |
Bayer Pharmaceuticals Corporation |
Aryl ureas with angiogenesis inhibiting activity
|
DK1580188T3
(da)
|
2002-02-11 |
2012-02-06 |
Bayer Healthcare Llc |
Forbindelser af arylurea som kinaseinhibitorer
|
CN1642422A
(zh)
*
|
2002-03-15 |
2005-07-20 |
西巴特殊化学品控股有限公司 |
4-氨基嘧啶及其在表面抗菌处理中的应用
|
US7405234B2
(en)
*
|
2002-05-17 |
2008-07-29 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
WO2003104178A1
(en)
*
|
2002-06-07 |
2003-12-18 |
Cortical Pty Ltd |
Napththalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (mif)
|
US20040009972A1
(en)
*
|
2002-06-17 |
2004-01-15 |
Ding Charles Z. |
Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase
|
EP1534862A4
(de)
*
|
2002-08-07 |
2007-10-10 |
Exelixis Inc |
Modulatoren von rabggt und verfahren zu deren verwendung
|
US7632858B2
(en)
*
|
2002-11-15 |
2009-12-15 |
Bristol-Myers Squibb Company |
Open chain prolyl urea-related modulators of androgen receptor function
|
JP2004346059A
(ja)
*
|
2003-01-28 |
2004-12-09 |
Takeda Chem Ind Ltd |
受容体作動薬
|
CA2514547A1
(en)
|
2003-01-28 |
2004-08-12 |
Takeda Pharmaceutical Company Limited |
Receptor agonists
|
US7157446B2
(en)
*
|
2003-05-02 |
2007-01-02 |
Bristol Myers Squibb Company |
Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
|
EP1636585B2
(de)
|
2003-05-20 |
2012-06-13 |
Bayer HealthCare LLC |
Diaryl-harnstoffe mit kinasehemmender wirkung
|
ME00294B
(me)
|
2003-07-23 |
2011-05-10 |
Bayer Pharmaceuticals Corp |
Fluoro supstituisana omega-karaboksiaril difenil urea za liječenje i prevenciju bolesti i stanja bolesti
|
EP1656451A2
(de)
|
2003-08-13 |
2006-05-17 |
Children's Hospital Medical Center |
Chimäre peptide für regulierung von gtpasen
|
EP1656156A2
(de)
|
2003-08-13 |
2006-05-17 |
Children's Hospital Medical Center |
Mobilisierung pluripotenter hämapoietischer stammzellen
|
US7256208B2
(en)
*
|
2003-11-13 |
2007-08-14 |
Bristol-Myers Squibb Company |
Monocyclic N-Aryl hydantoin modulators of androgen receptor function
|
JP4691041B2
(ja)
|
2003-11-20 |
2011-06-01 |
チルドレンズ ホスピタル メディカル センター |
Gtpアーゼ阻害剤および使用方法
|
US7820702B2
(en)
|
2004-02-04 |
2010-10-26 |
Bristol-Myers Squibb Company |
Sulfonylpyrrolidine modulators of androgen receptor function and method
|
US20050182105A1
(en)
*
|
2004-02-04 |
2005-08-18 |
Nirschl Alexandra A. |
Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
|
US7378426B2
(en)
|
2004-03-01 |
2008-05-27 |
Bristol-Myers Squibb Company |
Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
|
US7625923B2
(en)
|
2004-03-04 |
2009-12-01 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
US7696241B2
(en)
|
2004-03-04 |
2010-04-13 |
Bristol-Myers Squibb Company |
Bicyclic compounds as modulators of androgen receptor function and method
|
US7388027B2
(en)
*
|
2004-03-04 |
2008-06-17 |
Bristol-Myers Squibb Company |
Bicyclic compounds as modulators of androgen receptor function and method
|
WO2005089515A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
US20070293539A1
(en)
*
|
2004-03-18 |
2007-12-20 |
Lansbury Peter T |
Methods for the treatment of synucleinopathies
|
JP2007529555A
(ja)
*
|
2004-03-18 |
2007-10-25 |
ザ ブライハム アンド ウイメンズ ホスピタル, インコーポレイテッド |
シヌクレイノパチーを治療する方法
|
US20060106060A1
(en)
*
|
2004-03-18 |
2006-05-18 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies (Lansbury)
|
US20050272068A1
(en)
*
|
2004-03-18 |
2005-12-08 |
The Brigham And Women's Hospital, Inc. |
UCH-L1 expression and cancer therapy
|
EP1744751A4
(de)
*
|
2004-03-18 |
2010-03-10 |
Brigham & Womens Hospital |
Verfahren zur behandlung von synucleinopathien
|
US7323455B2
(en)
*
|
2004-03-24 |
2008-01-29 |
Wyeth |
7-aryl 1,5-dihydro-4,1-benzoxazepin-2(3H)-one derivatives and their use as progesterone receptor modulators
|
US20050272723A1
(en)
*
|
2004-04-27 |
2005-12-08 |
The Regents Of The University Of Michigan |
Methods and compositions for treating diseases and conditions associated with mitochondrial function
|
US10675326B2
(en)
|
2004-10-07 |
2020-06-09 |
The Board Of Trustees Of The University Of Illinois |
Compositions comprising cupredoxins for treating cancer
|
DK2362218T3
(en)
|
2004-11-05 |
2014-11-17 |
Janssen Pharmaceutica Nv |
Methods for monitoring the effectiveness of farnesyl transferase
|
ES2306278T3
(es)
|
2004-11-18 |
2008-11-01 |
Bristol-Myers Squibb Company |
Perla enterica recubierta que comprende ixabepilona.
|
US20060194821A1
(en)
*
|
2005-02-18 |
2006-08-31 |
The Brigham And Women's Hospital, Inc. |
Compounds inhibiting the aggregation of superoxide dismutase-1
|
WO2006104008A1
(ja)
*
|
2005-03-25 |
2006-10-05 |
Kissei Pharmaceutical Co., Ltd. |
ウレア誘導体、それを含有する医薬組成物およびそれらの医薬用途
|
US20060235006A1
(en)
*
|
2005-04-13 |
2006-10-19 |
Lee Francis Y |
Combinations, methods and compositions for treating cancer
|
US20060235028A1
(en)
*
|
2005-04-14 |
2006-10-19 |
Li James J |
Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
|
US8247419B2
(en)
*
|
2005-06-09 |
2012-08-21 |
Bristol-Myers Squibb Company |
Methods of identifying and treating individuals exhibiting mutant kit protein
|
US20060281788A1
(en)
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
|
CA2617056A1
(en)
|
2005-07-29 |
2007-02-08 |
Children's Hospital Medical Center |
Gtpase inhibitors and methods of use and crystal structure of rac-1 gtpase
|
WO2007024949A2
(en)
|
2005-08-25 |
2007-03-01 |
Schering Corporation |
Alpha2c adrenoreceptor agonists
|
US7700592B2
(en)
|
2005-08-25 |
2010-04-20 |
Schering Corporation |
α2C adrenoreceptor agonists
|
DE602006013501D1
(de)
|
2005-09-16 |
2010-05-20 |
Janssen Pharmaceutica Nv |
Cyclopropylamine als modulatoren des histamin-h3-rezeptors
|
EP1955073A2
(de)
*
|
2005-11-15 |
2008-08-13 |
Brystol-Myers Squibb Company |
Verfahren zur identifizierung und behandlung von mdr-1-überexpression zeigenden individuen mit proteintyrosinkinase-inhibitoren und kombinationen davon
|
US7622463B2
(en)
*
|
2006-02-14 |
2009-11-24 |
Vertex Pharmaceuticals Incorporated |
Dihydrodiazepines useful as inhibitors of protein kinases
|
BRPI0710548B8
(pt)
|
2006-04-20 |
2021-05-25 |
Janssen Pharmaceutica Nv |
inibidores de c-fms cinase, composição farmacêutica e forma de dosagem farmacêutica
|
US8697716B2
(en)
|
2006-04-20 |
2014-04-15 |
Janssen Pharmaceutica Nv |
Method of inhibiting C-KIT kinase
|
ATE510832T1
(de)
|
2006-04-20 |
2011-06-15 |
Janssen Pharmaceutica Nv |
Heterocyclische verbindungen als c-fms- kinasehemmer
|
RU2009125599A
(ru)
|
2006-12-04 |
2011-01-20 |
Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс (Us) |
Композиции и способы лечения рака cpg-богатой днк и купредоксинами
|
JP5385150B2
(ja)
|
2006-12-14 |
2014-01-08 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ピペラジニルおよびジアゼパニルベンズアミド誘導体の製造方法
|
WO2008089135A2
(en)
*
|
2007-01-12 |
2008-07-24 |
University Of South Florida |
Identification of biomarkers predictive of dasatinib effects in cancer cells
|
RU2009133473A
(ru)
|
2007-02-08 |
2011-03-20 |
Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс (Us) |
Композиции и способы для предотвращения рака с помощью купредоксинов
|
JP2010526825A
(ja)
*
|
2007-05-10 |
2010-08-05 |
エーエムアール テクノロジー インコーポレイテッド |
アリール置換およびヘテロアリール置換テトラヒドロベンゾ−1,4−ジアゼピンならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するためのその使用
|
WO2008144981A1
(fr)
*
|
2007-05-25 |
2008-12-04 |
Topharman Shanghai Co., Ltd. |
Procédés et intermédiaires pour préparer une 4-acétyl-2,3,4,5-tétrahydro-1h-1,4-benzodiazépine
|
MY148609A
(en)
|
2007-06-05 |
2013-05-15 |
Merck Sharp & Dohme |
Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer
|
JO3240B1
(ar)
|
2007-10-17 |
2018-03-08 |
Janssen Pharmaceutica Nv |
c-fms مثبطات كيناز
|
EP2234608A2
(de)
|
2007-12-11 |
2010-10-06 |
Viamet Pharmaceuticals, Inc. |
Metalloenzymhemmer mit metallbindenden teilen in kombination mit targeting-teilen
|
WO2009151683A2
(en)
*
|
2008-03-12 |
2009-12-17 |
Link Medicine Corporation |
Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
|
SG190620A1
(en)
*
|
2008-05-05 |
2013-06-28 |
Sanofi Aventis |
Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals
|
WO2011011027A1
(en)
|
2009-07-20 |
2011-01-27 |
Bristol-Myers Squibb Company |
Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
|
US8119129B2
(en)
*
|
2008-08-01 |
2012-02-21 |
Bristol-Myers Squibb Company |
Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
|
AU2009313927A1
(en)
*
|
2008-11-13 |
2010-05-20 |
Astrazeneca Ab |
Azaquinolinone derivatives and uses thereof
|
US20110060005A1
(en)
*
|
2008-11-13 |
2011-03-10 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
US20100331363A1
(en)
*
|
2008-11-13 |
2010-12-30 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
WO2010138487A1
(en)
*
|
2009-05-26 |
2010-12-02 |
Exelixis, Inc. |
BENZOXAZEPINES AS INHIBITORS OF PI3K/m TOR AND METHODS OF THEIR USE AND MANUFACTURE
|
CN102548986A
(zh)
|
2009-06-05 |
2012-07-04 |
链接医药公司 |
氨基吡咯烷酮衍生物及其用途
|
WO2011041152A1
(en)
|
2009-09-30 |
2011-04-07 |
Schering Corporation |
Novel compounds that are erk inhibitors
|
JP5856063B2
(ja)
|
2009-11-17 |
2016-02-09 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
治療特性を有する1,4−ベンゾジアゼピン−2,5−ジオンおよび関連化合物
|
WO2011125568A1
(ja)
|
2010-04-06 |
2011-10-13 |
日本曹達株式会社 |
含窒素複素環化合物及びその製造方法
|
AU2014201037B9
(en)
*
|
2010-04-06 |
2015-11-19 |
Nippon Soda Co., Ltd. |
Nitrogen-containing heterocyclic compound and method for producing same
|
US8999957B2
(en)
|
2010-06-24 |
2015-04-07 |
Merck Sharp & Dohme Corp. |
Heterocyclic compounds as ERK inhibitors
|
EP2613782B1
(de)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazolderivate als erk-hemmer
|
EP2654748B1
(de)
|
2010-12-21 |
2016-07-27 |
Merck Sharp & Dohme Corp. |
Indazolderivate als erk-hemmer
|
CN103442737B
(zh)
|
2011-01-20 |
2017-03-29 |
得克萨斯系统大学董事会 |
Mri标记、递送和提取系统及其制造方法和用途
|
CN102863474A
(zh)
|
2011-07-09 |
2013-01-09 |
陈小平 |
一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
|
CN102993239A
(zh)
|
2011-09-19 |
2013-03-27 |
陈小平 |
离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
|
WO2013064231A1
(en)
|
2011-10-31 |
2013-05-10 |
Phenex Pharmaceuticals Ag |
SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3)
|
WO2013166043A1
(en)
|
2012-05-02 |
2013-11-07 |
Children's Hospital Medical Center |
Rejuvenation of precursor cells
|
CN104684919A
(zh)
|
2012-07-31 |
2015-06-03 |
陶氏环球技术有限责任公司 |
制备烯烃聚合催化剂活化剂的方法
|
AU2013299922B2
(en)
|
2012-08-07 |
2018-06-21 |
Janssen Pharmaceutica Nv |
Process for the preparation of heterocyclic ester derivatives
|
JOP20180012A1
(ar)
|
2012-08-07 |
2019-01-30 |
Janssen Pharmaceutica Nv |
عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
|
EP2924044B1
(de)
|
2012-11-17 |
2018-10-31 |
Beijing Shuobai Pharmaceutical Co., LTD |
Platinverbindung eines malonsäurederivates mit abgangsgruppe mit amino oder alkylamino
|
JP6473133B2
(ja)
*
|
2013-03-15 |
2019-02-20 |
アラクセス ファーマ エルエルシー |
Krasg12cの共有結合性阻害剤
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Kras g12c之抑制劑
|
US10028503B2
(en)
|
2014-06-18 |
2018-07-24 |
Children's Hospital Medical Center |
Platelet storage methods and compositions for same
|
MX2017000181A
(es)
|
2014-06-27 |
2017-05-01 |
Univ California |
Celulas madre limbales de mamifero cultivadas, metodos para generarlas y sus usos.
|
AU2016245864C1
(en)
|
2015-04-10 |
2021-09-09 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
CA2982360A1
(en)
|
2015-04-15 |
2016-10-20 |
Liansheng Li |
Fused-tricyclic inhibitors of kras and methods of use thereof
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
PT3640345T
(pt)
|
2015-08-17 |
2021-12-29 |
Kura Oncology Inc |
Métodos de tratamento de doentes com cancro usando inibidores da farnesiltransferase
|
US10730867B2
(en)
|
2015-09-28 |
2020-08-04 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
US10689356B2
(en)
|
2015-09-28 |
2020-06-23 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
WO2017058768A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
US10875842B2
(en)
|
2015-09-28 |
2020-12-29 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
WO2017058792A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
EP3356353A1
(de)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitoren von kras-g12c-mutanten proteinen
|
US10975071B2
(en)
|
2015-09-28 |
2021-04-13 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
MX2018005967A
(es)
|
2015-11-16 |
2018-08-29 |
Araxes Pharma Llc |
Compuestos de quinazolina 2-sustituida que comprenden un grupo heterociclico sustituido y metodos de uso de los mismos.
|
US20190119758A1
(en)
|
2016-04-22 |
2019-04-25 |
Kura Oncology, Inc. |
Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
|
WO2017205536A2
(en)
*
|
2016-05-24 |
2017-11-30 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
WO2018064510A1
(en)
|
2016-09-29 |
2018-04-05 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
CN110312711A
(zh)
|
2016-10-07 |
2019-10-08 |
亚瑞克西斯制药公司 |
作为ras抑制剂的杂环化合物及其使用方法
|
DK3534885T3
(da)
|
2016-11-03 |
2021-04-12 |
Kura Oncology Inc |
Farnesyltransferase-inhibitorer til anvendelse i behandling af kræft
|
US11358959B2
(en)
|
2017-01-26 |
2022-06-14 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
EP3573954A1
(de)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fusionierte bicyclische benzoheteroaromatische verbindungen und verfahren zur verwendung davon
|
WO2018140513A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
US11136308B2
(en)
|
2017-01-26 |
2021-10-05 |
Araxes Pharma Llc |
Substituted quinazoline and quinazolinone compounds and methods of use thereof
|
US11059819B2
(en)
|
2017-01-26 |
2021-07-13 |
Janssen Biotech, Inc. |
Fused hetero-hetero bicyclic compounds and methods of use thereof
|
US10137121B2
(en)
|
2017-02-21 |
2018-11-27 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
EP3432883B1
(de)
|
2017-02-21 |
2021-07-28 |
Kura Oncology, Inc. |
Verfahren zur behandlung von krebs mit farnesyltransferase-inhibitoren
|
CN110869358A
(zh)
|
2017-05-25 |
2020-03-06 |
亚瑞克西斯制药公司 |
Kras的共价抑制剂
|
WO2018218069A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant kras, hras or nras
|
TW201906832A
(zh)
|
2017-05-25 |
2019-02-16 |
美商亞瑞克西斯製藥公司 |
用於癌症治療之化合物及其使用方法
|
MY200746A
(en)
|
2017-08-07 |
2024-01-13 |
Kura Oncology Inc |
Methods of treating cancer with farnesyltransferase inhibitors
|
US10806730B2
(en)
|
2017-08-07 |
2020-10-20 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
WO2019055877A1
(en)
|
2017-09-15 |
2019-03-21 |
Forma Therapeutics, Inc. |
TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
IL279734B1
(en)
|
2018-06-29 |
2024-07-01 |
Forma Therapeutics Inc |
CREB-binding protein (CBP) inhibition
|
UY38427A
(es)
|
2018-10-26 |
2020-05-29 |
Novartis Ag |
Métodos y composiciones para terapia con células oculares
|
CA3117968A1
(en)
|
2018-11-01 |
2020-05-07 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
CA3124616A1
(en)
|
2018-12-21 |
2020-06-25 |
Kura Oncology, Inc. |
Therapies for squamous cell carcinomas
|
US20220142983A1
(en)
|
2019-03-01 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
WO2020190604A1
(en)
|
2019-03-15 |
2020-09-24 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
CN113795253A
(zh)
|
2019-03-29 |
2021-12-14 |
库拉肿瘤学公司 |
用法呢基转移酶抑制剂治疗鳞状细胞癌的方法
|
TW202102218A
(zh)
|
2019-04-01 |
2021-01-16 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基(farnesyl)轉移酶抑制劑治療癌症的方法
|
US20220305001A1
(en)
|
2019-05-02 |
2022-09-29 |
Kura Oncology, Inc. |
Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
|
JP7502337B2
(ja)
*
|
2019-05-20 |
2024-06-18 |
カリフォルニア インスティチュート オブ テクノロジー |
Kras g12cインヒビター及びその使用
|
JP2023522784A
(ja)
|
2020-04-27 |
2023-05-31 |
ノバルティス アーゲー |
眼細胞療法のための方法及び組成物
|
US11801243B2
(en)
|
2020-09-23 |
2023-10-31 |
Forma Therapeutics, Inc. |
Bromodomain inhibitors for androgen receptor-driven cancers
|
US11795168B2
(en)
|
2020-09-23 |
2023-10-24 |
Forma Therapeutics, Inc. |
Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
|
CN115745960A
(zh)
*
|
2021-09-02 |
2023-03-07 |
中国科学院上海药物研究所 |
一类含喹啉酮酰胺的化合物及其制备方法、药物组合物和用途
|
CN114230529A
(zh)
*
|
2021-11-03 |
2022-03-25 |
河南大学 |
四氢喹喔啉磺酰胺衍生物及其制备方法与用途
|
WO2023143389A1
(zh)
*
|
2022-01-29 |
2023-08-03 |
江苏恒瑞医药股份有限公司 |
稠杂环类化合物、其制备方法及其在医药上的应用
|
WO2024097606A1
(en)
*
|
2022-10-31 |
2024-05-10 |
Eli Lilly And Company |
Ahr agonists
|